Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up – Should You Buy?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) gapped up before the market opened on Monday . The stock had previously closed at $38.24, but opened at $41.62. Celldex Therapeutics shares last traded at $38.3170, with a volume of 28,369 shares trading hands.

Key Celldex Therapeutics News

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Barzolvolimab met the primary endpoint and all key secondary endpoints in both the EMBARQ-CSU1 and EMBARQ-CSU2 Phase 3 trials. The treatment produced statistically significant improvements in weekly urticaria activity scores at Week 12 across both dose groups. Celldex Phase 3 results release
• Positive Sentiment: The company reported meaningful benefits in patients with omalizumab-refractory disease and in those with severe CSU or severe angioedema. Efficacy was sustained or improved through 24 weeks, supporting Celldex’s view that barzolvolimab could become a differentiated CSU therapy. The Pharma Letter article
• Positive Sentiment: Celldex plans to continue both studies through 52 weeks and anticipates submitting a biologics license application in 2027. The results prompted HC Wainwright to raise its price target from $42 to $64 and Cantor Fitzgerald to increase its target from $61 to $72, both retaining bullish ratings.
• Neutral Sentiment: The clinical and commercial outlook is being discussed in a company conference-call transcript, with investors evaluating the magnitude of the efficacy results, long-term durability and the path toward regulatory filing. Seeking Alpha transcript
• Negative Sentiment: Despite the positive trial readout, investors focused on safety concerns and the need for longer follow-up. Celldex described barzolvolimab as well tolerated through 24 weeks, but the ongoing 52-week data and regulatory review remain important risks. Economic Times article
• Negative Sentiment: The sharp decline suggests expectations were already elevated ahead of the catalyst, leading to a possible “sell-the-news” response even though the trials succeeded. The reaction reflects investor positioning and perceived risk rather than a failure of the Phase 3 studies. Quiver Quantitative analysis

Analysts Set New Price Targets

A number of brokerages recently weighed in on CLDX. Canaccord Genuity Group dropped their price target on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Barclays upped their price objective on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. UBS Group raised their target price on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Finally, Wells Fargo & Company boosted their price target on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.17.

Celldex Therapeutics Trading Down 11.6%

The stock has a 50-day simple moving average of $39.03 and a 200 day simple moving average of $34.84. The stock has a market capitalization of $2.63 billion, a price-to-earnings ratio of -7.70 and a beta of 0.84.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.73 million. Sell-side analysts expect that Celldex Therapeutics, Inc. will post -4.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLDX. Nykredit A S acquired a new position in Celldex Therapeutics in the second quarter worth approximately $67,000. Diversified Trust Co bought a new position in Celldex Therapeutics during the first quarter valued at approximately $223,000. Walleye Capital LLC acquired a new stake in Celldex Therapeutics in the first quarter valued at approximately $258,000. Amundi acquired a new stake in Celldex Therapeutics in the first quarter valued at approximately $297,000. Finally, Glenmede Trust Co. NA bought a new stake in Celldex Therapeutics in the first quarter worth approximately $357,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for diseases with significant unmet medical needs. The company’s research programs address conditions in immunology, inflammation, oncology and other areas where targeted immune-system modulation may provide therapeutic benefits.

Celldex’s lead investigational product is barzolvolimab, an antibody designed to block the KIT receptor and reduce mast cells. The therapy is being studied in immune-mediated diseases, including chronic spontaneous urticaria and prurigo nodularis.